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tion, drug cost, and therapeutic outcomes. Although
additional data is required for conclusive evidence, the
preliminary data suggests a downward trend in antibiotic
costs in the ICU.
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INTRODUCTION: The impact of prescription NSAIDS
on the GI tract is well documented. The easy availability
of low-dose OTC NSAIDs may lead to iatrogenic GI dis-
ease invisible to the medical community. OBJECTIVE:
To determine if the role and rate of GI adverse side ef-
fects were related to over-the-counter NSAID use. METH-
ODS: Data were obtained by structured telephone survey
administered to a nationally representative, randomly se-
lected US adult population (40 years). We compared re-
sponses of regular OTC NSAID users (defined as use for
at least 4 of 7 days, and 16 of 30 days prior to the sur-
vey) with those of non-users. Logistic regression com-
pared the likelihood of GI symptoms and use of GI med-
ications, after adjusting for age, gender, ethnicity, and
self-reported health status. RESULTS: We surveyed 535
OTC NSAID users (mean age  63, range 40–96) and
1068 non users (mean age  63, range 40–93). NSAID
users were 2.1 times more likely to report GI symptoms
than non users (P  0.0001), and 2.7 times more likely
to have taken OTC GI medications than non users (P 
0.0001) during past 30 days. 84.8% of NSAID users tak-
ing GI medications for their symptoms had not informed
a physician of GI symptoms. CONCLUSIONS: OTC
NSAIDs are widely used and thought to be safe at low
dose. Our data show users commonly experience GI
symptoms, for which they self-medicate without inform-
ing their physician. This may represent an important bur-
den of hidden GI disease.
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Peptic ulcers, erosions of the stomach lining, afflict greater
than 25 million Americans. Ulcers diminish quality of life
and cost nearly $6 billion dollars annually. OBJECTIVE:
To decrease unnecessary medical utilization, histamine-2-
blocker (H2) and proton-pump-inhibitor (PPI) utilization
and improve quality of life for peptic ulcer patients by us-
ing educational intervention to increase compliance to
drug regimens for H. pylori eradication. METHODS: Pa-
tients were targeted for specific antibiotic therapies via
drug data and verified at first telephone contact. A ques-
tionnaire developed and validated by Lewin-TAG was
used for data collection. Data were collected for a 90 day
period pre/post therapy regarding hospitalizations, doc-
tor visits, emergency room visits, lost productivity, out-
patient surgeries, pharmacy utilization and medical test/
procedures resulting from the disease. Quality of life
questions measured how often usual activities and work
productivity were reduced due to peptic ulcer disease. Pa-
tient satisfaction with the program was also measured.
RESULTS: (n  1993, response rate  94.5%) Patient
compliance to drug regimen was found to be 95.7%.
Hospitalizations were reduced by 73% (P  0.0001),
doctor visits by 49% (P  0.0001). Emergency room vis-
its were reduced by 72% (P  0.0001) and outpatient
surgeries by 56% (P  0.0001). Finally, a decrease of
54% in H2/PPI usage (P  0.0001) and a decrease of
76% in medical tests/procedures (P  0.0001) were seen.
Participants reported a 13% decrease in pain and symp-
toms (P  0.005) and a 34% increase in productivity
(P  0.0001). Participant satisfaction rate with the pro-
gram was 98.6%. CONCLUSION: The CarePatterns
peptic ulcer disease program improves patients’ quality
of life, reduces unnecessary medical and pharmacy utili-
zation, and is cost-effective.
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OBJECTIVE: The aim of this project is to evaluate the ef-
fectiveness of a program including practice guidelines,
treatment algorithms, and peer comparison feedback in
changing physicians’ prescribing behaviors in the treat-
ment of patients with peptic ulcer disease (PUD). METH-
ODS: A prospective intervention with a control group
was conducted to determine the impact of a PUD infor-
mation dissemination program targeted towards physi-
cians in a managed care setting. Pharmacy claims data
were used to assess impact of the program on utilization
of eradication therapy, long-term antisecretory utiliza-
tion, and total cost of drug therapy per patient. RE-
SULTS: Preliminary data from a 3-month follow-up pe-
riod are available and indicate that utilization of eradication
